Mucuna pruriens improves motor symptoms in Parkinson's disease with benefits comparable to levodopa
Mucuna pruriens was supported by Grade A evidence for motor improvement in Parkinson's disease, showing benefits comparable to levodopa and increased ON time without worsening dyskinesia. It also reduced dyskinesia with Grade B evidence.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Mucuna pruriens improves motor symptoms in Parkinson's disease with benefits comparable to levodopa The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Mucuna pruriens improves motor symptoms in Parkinson's disease with benefits comparable to levodopa
This conclusion is most relevant to: Patients with Parkinson's disease.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Plant-derived therapies in Parkinson's disease: a systematic review of clinical evidence. (Journal of neural transmission (Vienna, Austria : 1996), 2026) —
How It Works
The proposed biological pathway:
- ▸Mucuna pruriens contains natural levodopa
- ▸Provides exogenous dopamine precursor
- ▸Increases dopamine availability in the brain
- ▸Result: Improved motor function and reduced dyskinesia
Who Might Benefit
Evidence fit by population:
- ▸Patients with Parkinson's disease
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Evidence grading reflects study hierarchy rather than certainty of clinical effect
- ▸Limited number of studies and small sample sizes
- ▸Interpretation requires caution due to limited evidence
Frequently Asked Questions
Is Mucuna pruriens as effective as standard levodopa for Parkinson's disease?▼
The study found Mucuna pruriens showed motor benefits comparable to levodopa, with Grade A evidence for motor improvement.
Does Mucuna pruriens worsen dyskinesia in Parkinson's patients?▼
No, the study reported that Mucuna pruriens increased ON time without worsening dyskinesia, and even reduced dyskinesia with Grade B evidence.
What grade of evidence supports Mucuna pruriens for motor symptoms?▼
Grade A evidence supports its use for motor improvement, while Grade B evidence supports reduction of dyskinesia.
Are there any safety concerns with Mucuna pruriens in Parkinson's disease?▼
The abstract does not report specific safety concerns, but notes that overall evidence is limited and interpretation should be cautious.
References
- 1.Sukmueng N, Phokaewvarangkul O, Bhidayasiri R. “Plant-derived therapies in Parkinson's disease: a systematic review of clinical evidence..” Journal of neural transmission (Vienna, Austria : 1996), 2026. PMID: 42489905 DOI: 10.1007/s00702-026-03239-4